Endothelin in diabetic renal disease

Endothelin in Renal Physiology and Disease

Volumn 172, Issue , 2011, Pages 139-148

  Benz, Kerstin ^a   Amann, Kerstin ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIN; ENDOTHELIN A RECEPTOR;

ANIMAL; DIABETIC NEPHROPATHY; DRUG ANTAGONISM; HUMAN; PHYSIOLOGY; REVIEW;

ANIMALS; DIABETIC NEPHROPATHIES; ENDOTHELINS; HUMANS; RECEPTOR, ENDOTHELIN A;

EID: 84926120763     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1159/000328695     Document Type: Chapter

References (51)

1. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411-415.
2. Barton M, Nett P, Amann K, Teixeira M:Anti-Inflammatory Effects of Endothelin Receptor Antagonists and their Importance for Treating Human Disease. Front Cardiovasc Drug Discov 2010;1:236-258.
3. Rebibou JM, He CJ, Delarue F, Peraldi MN, Adida C, Rondeau E, Sraer JD: Functional endothelin 1 receptors on human glomerular podocytes and mesangial cells. Nephrol Dial Transplant 1992;7:288-292.
4. Uchida K, Uchida S, Nitta K, Yumura W, Nihei H: Regulated expression of endothelin converting enzymes in glomerular endothelial cells. J Am Soc Nephrol 1997;8:580-585.
5. Karet FE, Davenport AP: Localization of endothelin peptides in human kidney. Kidney Int 1996;49:382-387.
6. Karet FE: Endothelin peptides and receptors in human kidney. Clin Sci (Lond) 1996;91:267-273.
7. Wendel M, Knels L, Kummer W, Koch T:Distribution of endothelin receptor subtypes ETA and ETB in the rat kidney. J Histochem Cytochem 2006;54:1193-1203.
8. Schildroth J, Rettig-Zimmermann J, Kalk P, Steege A, Fahling M, Sendeski M, Paliege A, Lai EY, Bachmann S, Persson PB, Hocher B, Patzak A: Endothelin type A and B receptors in the control of afferent and efferent arterioles in mice. Nephrol Dial Transplant 2011;26:779-789.
9. Kohan DE: Endothelin, hypertension and chronic kidney disease: new insights. Curr Opin Nephrol Hypertens 2010;19:134-139.
10. Saleh MA, Boesen EI, Pollock JS, Savin VJ, Pollock DM: Endothelin-1 increases glomerular permeability and inflammation independent of blood pressure in the rat. Hypertension 2010;56:942-949.
11. Kohan DE: Biology of endothelin receptors in the collecting duct. Kidney Int 2009;76:481-486.
12. + channel through betaPix/14-3-3/Nedd4-2. J Am Soc Nephrol 2010;21:833-843.
13. Ortmann J, Amann K, Brandes RP, Kretzler M, Munter K, Parekh N, Traupe T, Lange M, Lattmann T, Barton M: Role of podocytes for reversal of glomerulosclerosis and proteinuria in the aging kidney after endothelin inhibition. Hypertension 2004;44:974-981.
14. Sorokin A, Kohan DE: Physiology and pathology of endothelin-1 in renal mesangium. Am J Physiol Renal Physiol 2003;285:F579-F589.
15. Barton M: Reversal of proteinuric renal disease and the emerging role of endothelin. Nat Clin Pract Nephrol 2008;4:490-501.
16. Morigi M, Buelli S, Angioletti S, Zanchi C, Longaretti L, Zoja C, Galbusera M, Gastoldi S, Mundel P, Remuzzi G, Benigni A: In response to protein load podocytes reorganize cytoskeleton and modulate endothelin-1 gene: implication for permselective dysfunction of chronic nephropathies. Am J Pathol 2005;166:1309-1320.
17. Groop PH, Thomas MC, Moran JL, Waden J, Thorn LM, Makinen VP, Rosengard-Barlund M, Saraheimo M, Hietala K, Heikkila O, Forsblom C: The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes. Diabetes 2009;58:1651-1658.
18. Tang SC: Diabetic nephropathy: a global and growing threat. Hong Kong Med J 2010;16:244-245.
19. Osterby R, Hartmann A, Nyengaard JR, Bangstad HJ: Development of renal structural lesions in type-1 diabetic patients with microalbuminuri. Observations by light microscopy in 8-year follow-up biopsies. Virchows Arch 2002;440:94-101.
20. Dronavalli S, Duka I, Bakris GL: The pathogenesis of diabetic nephropathy. Nat Clin Pract Endocrinol Metab 2008;4:444-452.
21. Jauregui A, Mintz DH, Mundel P, Fornoni A:Role of altered insulin signaling pathways in the pathogenesis of podocyte malfunction and microalbuminuria. Curr Opin Nephrol Hypertens 2009;18:539-545.
22. Khan MA, Dashwood MR, Mumtaz FH, Thompson CS, Mikhailidis DP, Morgan RJ:Upregulation of endothelin A receptor sites in the rabbit diabetic kidney: potential relevance to the early pathogenesis of diabetic nephropathy. Nephron 1999;83:261-267.
23. Bruzzi I, Benigni A: Endothelin is a key modulator of progressive renal injury: experimental data and novel therapeutic strategies. Clin Exp Pharmacol Physiol 1996;23:349-353.
24. Zanatta CM, Gerchman F, Burttet L, Nabinger G, Jacques-Silva MC, Canani LH, Gross JL: Endothelin-1 levels and albuminuria in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2008;80:299-304.
25. Hargrove GM, Dufresne J, Whiteside C, Muruve DA, Wong NC: Diabetes mellitus increases endothelin-1 gene transcription in rat kidney. Kidney Int 2000;58:1534-1545.
26. Sudano I, Hermann M, Ruschitzka FT:Endothelin-receptor antagonists in arterial hypertension: further indications? Curr Hypertens Rep 2007;9:59-65.
27. Ak G, Buyukberber S, Sevinc A, Turk HM, Ates M, Sari R, Savli H, Cigli A: The relation between plasma endothelin-1 levels and metabolic control, risk factors, treatment modalities, and diabetic microangiopathy in patients with type 2 diabetes mellitus. J Diabetes Complications 2001;15:150-157.
28. Sarafidis PA, Lasaridis AN: Insulin resistance and endothelin: another pathway for renal injury in patients with the cardiometabolic syndrome? J Cardiometab Syndr 2008;3:183-187.
29. Sarafidis PA, Bakris GL: Review: insulin and endothelin: an interplay contributing to hypertension development? J Clin Endocrinol Metab 2007;92:379-385.
30. Strawbridge AB, Elmendorf JS, Mather KJ: Interactions of endothelin and insulin:expanding parameters of insulin resistance. Curr Diabetes Rev 2006;2:317-327.
31. Lteif A, Vaishnava P, Baron AD, Mather KJ: Endothelin limits insulin action in obese/insulin-resistant humans. Diabetes 2007;56:728-734.
32. Gross ML, El-Shakmak A, Szabo A, Koch A, Kuhlmann A, Munter K, Ritz E, Amann K: ACE-inhibitors but not endothelin receptor blockers prevent podocyte loss in early diabetic nephropathy. Diabetologia 2003;46:856-68.
33. Bruzzi I, Remuzzi G, Benigni A: Endothelin:a mediator of renal disease progression. J Nephrol 1997;10:179-183.
34. Benigni A, Perico N, Remuzzi G: Research on renal endothelin in proteinuric nephropathies dictates novel strategies to prevent progression. Curr Opin Nephrol Hypertens 2001;10:1-6.
35. Kitamura A, Kagami S, Urushihara M, Kondo S, Yoshizumi M, Tamaki T, Kuroda Y:Endothelin-1 is a potent stimulator of alpha-1beta1 integrin-mediated collagen matrix remodeling by rat mesangial cells. Biochem Biophys Res Commun 2002;299:555-561.
36. Hocher B, Thone-Reineke C, Rohmeiss P, Schmager F, Slowinski T, Burst V, Siegmund F, Quertermous T, Bauer C, Neumayer HH, Schleuning WD, Theuring F: Endothelin-1 transgenic mice develop glomerulosclerosis, interstitial fibrosis, and renal cysts but not hypertension. J Clin Invest 1997;99:1380-1389.
37. Osterby R, Tapia J, Nyberg G, Tencer J, Willner J, Rippe B, Torffvit O: Renal structures in type 2 diabetic patients with elevated albumin excretion rate. APMIS 2001;109:751-761.
38. Barton M: Therapeutic potential of endothelin receptor antagonists for chronic proteinuric renal disease in humans. Biochim Biophys Acta 2010;1802:1203-1213.
39. Dhaun N, Macintyre IM, Melville V, Lilitkarntakul P, Johnston NR, Goddard J, Webb DJ: Blood pressure-independent reduction in proteinuria and arterial stiffness after acute endothelin-a receptor antagonism in chronic kidney disease. Hypertension 2009;54:113-119.
40. Dhein S, Hochreuther S, Aus Dem Spring C, Bollig K, Hufnagel C, Raschack M: Longterm effects of the endothelin(A) receptor antagonist LU 135252 and the angiotensinconverting enzyme inhibitor trandolapril on diabetic angiopathy and nephropathy in a chronic type I diabetes mellitus rat model. J Pharmacol Exp Ther 2000;293:351-359.
41. Gross ML, Ritz E, Schoof A, Helmke B, Parkman A, Tulp O, Munter K, Amann K:Renal damage in the SHR/N-cp type 2 diabetes model: comparison of an angiotensinconverting enzyme inhibitor and endothelin receptor blocker. Lab Invest 2003;83:1267-1277.
42. Watson AM, Li J, Schumacher C, de Gasparo M, Feng B, Thomas MC, Allen TJ, Cooper ME, Jandeleit-Dahm KA: The endothelin receptor antagonist avosentan ameliorates nephropathy and atherosclerosis in diabetic apolipoprotein E knockout mice. Diabetologia 2010;53:192-203.
43. Ortmann J, Nett PC, Celeiro J, Hofmann-Lehmann R, Tornillo L, Terracciano LM, Barton M: Downregulation of renal endothelin-converting enzyme 2 expression in early autoimmune diabetes. Exp Biol Med (Maywood) 2006;231:1030-1033.
44. Ortmann J, Nett PC, Celeiro J, Traupe T, Tornillo L, Hofmann-Lehmann R, Haas E, Frank B, Terraciano LM, Barton M:Endothelin inhibition delays onset of hyperglycemia and associated vascular injury in type I diabetes: evidence for endothelin release by pancreatic islet beta-cells. Biochem Biophys Res Commun 2005;334:689-695.
45. Honing ML, Hijmering ML, Ballard DE, Yang YP, Padley RJ, Morrison PJ, Rabelink TJ: Selective ET(A) receptor antagonism with ABT-627 attenuates all renal effects of endothelin in humans. J Am Soc Nephrol 2000;11:1498-1504.
46. Goddard J, Johnston NR, Hand MF, Cumming AD, Rabelink TJ, Rankin AJ, Webb DJ: Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure: a comparison of selective and combined endothelin receptor blockade. Circulation 2004;109:1186-1193.
47. Wenzel RR, Littke T, Kuranoff S, Jurgens C, Bruck H, Ritz E, Philipp T, Mitchell A:Avosentan reduces albumin excretion in diabetics with macroalbuminuria. J Am Soc Nephrol 2009;20:655-664.
48. Mann JF, Green D, Jamerson K, Ruilope LM, Kuranoff SJ, Littke T, Viberti G: Avosentan for overt diabetic nephropathy. J Am Soc Nephrol 2010;21:527-535.
49. Ritz E, Wenzel R: Endothelin receptor antagonists in proteinuric renal disease:every rose has its thorn. J Am Soc Nephrol 2010;21:392-394.
50. Sarafidis PA, Lasaridis AN: Diabetic nephropathy:endothelin antagonism for diabetic nephropathy. Nat Rev Nephrol 2010;6:447-449.
51. Kohan DE, Pritchett Y, Molitch M, Wen S, Garimella T, Audhya P, Andress DL:Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy. J Am Soc Nephrol 2011;22:763-772.